การนำแนวทางการให้บริบาลทางเภสัชกรรมและการเลือกใช้ magnesium, riboflavin และ coenzyme Q10 เพื่อป้องกันไมเกรนกลับเป็นซ้ำไปใช้ในร้านยา

Main Article Content

ณัฏยา อุ่นจิตต์
ปวีณา สนธิสมบัติ

บทคัดย่อ

วัตถุประสงค์: เพื่อจัดทำแนวทางการให้คำปรึกษาและเลือกใช้ผลิตภัณฑ์เสริมอาหาร (ผลิตภัณฑ์ฯ) ที่ประกอบด้วยmagnesium, riboflavin หรือcoenzyme Q10 เพื่อป้องกันไมเกรนกลับเป็นซ้ำ (แนวทางฯ) ประเมินความพึงพอใจของเภสัชกรชุมชนต่อแนวทางฯ และนำแนวทางฯ ไปประเมินส่วนประกอบและขนาดใช้ของผลิตภัณฑ์ฯ ที่จำหน่ายในร้านขายยาวิธีการ: ผู้วิจัยสืบค้นวรรณกรรมปฐมภูมิเพื่อจัดทำแนวทางฯ การศึกษาประเมินความพึงพอใจต่อการนำแนวทางฯ ฉบับสมบูรณ์ไปใช้เป็นเวลา 1 เดือนโดยเภสัชกรจากร้านขายยาในเขตอำเภอเมืองจังหวัดปทุมธานีจำนวน 94 คน ผู้วิจัยใช้แนวทางฯ ประเมินผลิตภัณฑ์ฯ จำนวน 48 รายการที่จำหน่ายในร้านขายยาในประเด็นส่วนประกอบและขนาดใช้ ผลการวิจัย: แนวทางฯ ประกอบด้วยผลการทบทวนวรรณกรรมเกี่ยวกับประสิทธิภาพและความปลอดภัยจากการใช้magnesium, riboflavin หรือ coenzyme Q10 ในการป้องกันไมเกรนกลับเป็นซ้ำและแนวทางการเลือกใช้ผลิตภัณฑ์ฯ เภสัชกรพึงพอใจต่อแนวทางฯ ฉบับสมบูรณ์ในระดับมาก (คะแนนเฉลี่ย 4.2±0.7 จากคะแนนเต็ม 5) ความพึงพอใจในด้านความเข้าใจในเนื้อหาและการนำไปใช้ด้านรูปแบบของแนวทางฯ และด้านภาพรวมของแนวทางฯ มีคะแนน 4.2±0.7,4.1±0.7 และ 4.3±0.7 จากคะแนนเต็ม 5 ตามลำดับผลิตภัณฑ์ฯ จำนวน 4 จาก 48 รายการ (ร้อยละ 8.3) มีส่วนประกอบและขนาดการใช้ตามหลักฐานทางวิชาการ สรุป: เนื้อหาของแนวทางฯ ที่จัดทำขึ้นมีประโยชน์ในการแนะนำผลิตภัณฑ์ฯ เพื่อป้องกันไมเกรนกลับเป็นซ้ำ ผลิตภัณฑ์ฯ ในร้านขายยาของเขตอำเภอเมือง จังหวัดปทุมธานีจำนวนน้อยที่มีส่วนประกอบและขนาดใช้เป็นไปตามหลักฐานทางวิชาการ

Article Details

บท
บทความวิจัย

References

GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954-76.

Phanthumchinda K, Kamol-Ratanakul P. Prevalence of primary headache in central region of Thailand: a cross-sectional survey. J Neurol 1999; 246suppl 1: S319.

Phanthumchinda K, Sithi-Amorn C. Prevalence and clinical features of migraine: a community survey in Bangkok, Thailand. Headache 1989; 29: 594-7.

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-9

Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people's life. Headache 2019; 20: 41.

Blumenfeld A, Varon S, Wilcox T, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011; 31: 301-15.

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211-59.

Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 2019; 18: 891-902.

Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 2015; 55: 103-22.

Puledda F, Shields K. Non-pharmacological approaches for migraine. Neurotherapeutics 2018; 15: 336-45.

Chaibi A, Tuchin P, Russell MB. Manual therapies for migraine: a systematic review. Headache 2011; 12: 127-33.

Luedtke K, Allers A, Schulte LH, May A. Efficacy of intervention used by physiotherapists for patients with headache and migraine-systematic review and meta-analysis. Cephalalgia 2016; 36: 474-92.

Dinner HC, Krenfeld K, Boewing G, Lungenhausen M, Maier C, Molsberger A, et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicenter randomized controlled trial. Lancet Neurol 2006; 5: 310-6.

Xu J, Zhang FQ, Pei J, Ji J. Acupuncture for migraine without aura: a systematic review and meta-analysis. J Integr Med 2018; 16: 312-21.

Okoli GN, Rabbani R, KashaniHH, Wierzbowski AK, Neilson C, Mansouri B, et al. Vitamins and minerals for migraine prophylaxis: a systematic review. Can J Neurol Sci 2019; 46: 224-33.

Diener HC, Matias-Guiu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002; 22: 209-21.

Sadeghian H, Motiei-Langroundi R. Comparison of levetiracetam and sodium valproate in migraine prophylaxis: a randomized placebo-controlled study. Ann Indian Acad Neurol 2015; 18: 45-8.

Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention. Arch Neurol 2004; 61: 490-5.

Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 2016; 87: 741-49.

Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, et al. Migraine and sleep disorders: a systematic review. Headache 2020; 21: 126.

Nye BL, Thadani VM. Migraine and epilepsy: review of the literature. Headache 2015; 55: 359-80.

Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1152407 subjects. BMJ Open 2018; 8: e020498.

Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis a randomized controlled trial. Neurology 1998; 50: 466-70.

TarighatEsfanjani A, Mahdavi R, Ebrahimi Mame- ghani M, Talebi M, Nikniaz Z, Safaiyan A. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res 2012; 150: 42–8.

Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257-63.

Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64: 713-5.

Takahashi M, Uchino N. Risk factors of hypermag- nesemia in end-stage cancer patients hospitalized in a palliative care unit. Ann Palliat Med 2020; 9: 4308-14.

Saengcharoen W, Buasri N, Khantapokha B, Lerkiatbundit S. Public knowledge and factors associated with inappropriate analgesic use: a survey in Thailand. Int J Pharm Pract 2016; 24: 22-9.

Korsanan S. Form and capacity of pharmacists in their responsibilities in pharmacies that are certified for high quality medicines. Journal of Human Resource Intelligence 2012; 7: 47-52.

Sangkar P, Hongsamoot D. Practice interest and readiness of community pharmacists toward communitypharmacists’ role development. Journal of Health Science of Thailand 2010; 19: 982-95.

BuanuiN.Readiness of drug store operators in Public Health Inspection Area 7 to comply with drug store standard criteria in the drug store quality develop- ment and certification project [master thesis]. Bangkok: Sukhothai Thammathirat; 2009.

Hoffmann W, Herzog B, Muhlig S, Kayser H, Fabian R, Thomsen M, et al. Pharmaceutical care for migraine and headache patients: a community-based randomized intervention. Ann Pharmacother 2008; 42: 1804-13.

OTC Products: A study of pharmacists' recommen- dations. Pharm Times 2001; 67: 10-30.

The Neurological Society of Thailand. Thai Headache Society Guideline for medical practice diagnosis and treatment migraine headache. Bangkok: Thanapress; 2022.

Sripairoj N. Basic research principles. Bangkok: Suksaporn; 1984.

Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician 2019; 99: 17-24.

Nattagh-Eshtivani E, Sani MA, Dahri M, Ghalichi F, Ghavami A, Arjang P, Tarighat-Esfanjani A. The role of nutrients in the pathogenesis and treatment of migraine headaches: review. Biomed Pharmaco- ther 2018; 102: 317-25.

Pringsheim T, Davenport W, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society Guideline for Migraine Prophylaxis. Can J Neurol Sci 2012; 39 Suppl2: S1-59.

Köseoglu E, Talaslioglu A, SaffetGönül A, Kula M. The effects of magnesium prophylaxis in migraine without aura. Magnesium Res 2008; 21: 101-8.

Pfaffenrath V, Wessely P, Meyer C. Magnesium in the prophylaxis of migraine-a double-blind placebo-controlled study. Cephalalgia 1996; 16: 436–40.

Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994; 14: 328-29.

Sandor PS, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the Intensity dependence of auditory evoked cortical potentials. Headache 2000; 40: 30–5.

Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl K, Arnold G. High‐dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004; 11: 475-7.

Nambiar NJ, Aiyappa C, Srinivasa R. Oral riboflavin versus oral propranolol in migraine prophylaxis: an open label randomized controlled trial. Neurol Asia 2011; 16: 223-9.

Athaillah YD, Saing JH, Saing HB, Lelo A. Riboflavin as migraine prophylaxis in adolescents. PaediatrIndones2012; 52: 132-7.

Rahimdel A, Zeinali A, Yazdian-anari P, Hajizadeh R, Arefnia E. Effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis: a randomized clinical trial. Electron Phys 2015; 7: 1344-8.

MICROMEDEX® [Database on the internet]. Colorado: Thomson Reuters (Healthcare); c1973-2024. Toxicology, Riboflavin; [cited 2021 Apr 23]. Available from: www.micromedexsolution.com (Subscription required to view)

Food and Nutrition Board, Institute of Medicine. Dietary reference intakes: thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press: 2000.

Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002; 22: 137–41.

Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of coenzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011; 31: 897–905.

Shoeibi A, Olfati N, SoltaniSabi M, Salehi M, Mali S, Akbari Oryani M. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg2017; 117: 103-9.

Gaul C, Diener HC, Danesch U, Migravent® Study Group. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. Headache 2015; 16: 516.

Hajihashemi P, Askari G, Khorvash F, Reza Maracy M, Nourian M. The effects of concurrent coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Cephalalgia 2019; 39: 648-54.

Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990; 30: 596-608.

Fred DD, Richard PB, Paul RW. User acceptance of computer technology: a comparison of two theoretical models. Manag Sci 1989; 35: 982-1003.

Aungst TD, Miranda AC, Serag-Bolos ES. How mobile devices are changing pharmacy practice. Am J Health Syst Pharm 2015; 72: 494-500.

Wenzel RG, Lipton RB, Diamond ML, Cady R. Migraine therapy: a survey of pharmacists' knowledge, attitudes, and practice patterns. Headache 2005; 45: 47-52.

Lanteri-Minet M, Nachit-Ouinekh F, Mihout B, Slama A, El Hasnaoui A. The treatment of migraine by pharmacists: a French multicenter study. Rev Neurol 2004; 160: 441-6.

Kaur M, Sharma N. Electronic service quality and customer satisfaction: A study of customer loyalty with special reference to tourism industry. Amity Business Rev 2015; 16: 100-14.

Chokjaroenrat O. Assessment of oral contraceptive flowchart using in community pharmacy: Case studies at community pharmacies in Phasi Charoen, Bangkok [master thesis]. Pitsanuloke: Naresuan University; 2016.

Tantisoponwanish N, Polnok A. Development of a common gynecological disease history elicitation instrument for Myanmar workers to be implemented at drug stores. Journal of Community Development and Life Quality 2017; 5: 575-85.

Konghorm N, Thananitisak C. Test of the tool for preventing and managing drug interaction involving HMG-CoA reductase inhibitor within pharmacies. Thai Journal of Pharmacy Practice2019; 11: 378-86.

Lueangaram S. Development of Burmese language history taking manual in common gastro-intestinal disease in drugstores [master thesis]. Pitsanuloke: Naresuan University; 2018.